We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 831

Follow-on biologics: a patent litigation perspective

  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • -
  • USA
  • -
  • August 22 2009

In whatever form biosimilar legislation might take, patent holders will need to review their patent portfolios carefully

Federal Circuit confirms the written description requirement for patent applications

  • Nutter McClennen & Fish LLP
  • -
  • USA
  • -
  • May 17 2010

On March 22, 2010, the Federal Circuit handed down an en banc decision holding that the "written description" requirement for patent applications is distinct from the enablement requirement

Court denies motion for Mareva injunction in a Section 8 damages action

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 11 2010

On March 2, 2010, the Federal Court denied a motion brought by Novopharm Limited (“Novopharm”) seeking a Mareva injunction enjoining Eli Lilly Canada Inc. (“Lilly Canada”) from transferring its revenues to its parent company, Eli Lilly and Company (“Lilly US”

AstraZeneca v Novopharm, motion to adduce video-recordings of cross-examinations of expert witnesses in a PMNOC Regulations case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

AstraZeneca brought a motion seeking an order that video-recordings of cross-examinations of expert witnesses in the proceedings be filed as part of the Application Record and available at the hearing

Recent developments in clinical data exclusivity

  • Becerril Coca & Becerril SC
  • -
  • Mexico
  • -
  • December 17 2012

Mexico, along with the United States and Canada, was one of the first countries to sign data protection provisions in a free trade agreement. The North

Canada’s Access to Medicines Regime

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • March 25 2010

The World Trade Organization (the "WTO") obliges WTO countries, such as Canada, to help developing countries acquire affordable generic medicines in order to combat diseases epidemic diseases

Preparing your patent portfolio for follow-on biologics

  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • -
  • USA
  • -
  • March 29 2010

On March 23, 2010, President Obama signed into law health insurance reform legislation, H.R. 3590 , a bill which has generated enormous media coverage and publicity

If it is obvious to try, it still might not be obvious

  • McDermott Will & Emery
  • -
  • United Kingdom
  • -
  • September 10 2008

In Conor Medsystems Inc v Angiotech Pharmaceuticals Inc 2008 UKHL 49, the House of Lords has revisited the test of “obvious to try” most often raised in patent validity actions

Repercussions expected on medicine advertising campaign in Mexico

  • Olivares
  • -
  • Mexico
  • -
  • November 2 2009

A recent high-profile marketing initiative by a Mexican pharmaceutical company appears to be a clear example of unfair competition

PMPRB releases 2006 Annual Report

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • August 15 2007

The Patented Medicine Prices Review Board (PMPRB) tabled its 2006 Annual Report before Parliament on July 18